Post

New research · Urology
European journal of nuclear medicine and molecular imaging · 1d
Cohort studyEuropean journal of nuclear medicine and molecular imaging · 2026

Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy.

Christian Immanuel, Thomas Büttner, Alois M Sprinkart … Milka Marinova
Read paper
UrologyCohort study

Lower skeletal muscle radiodensity is associated with reduced overall survival in metastatic prostate cancer.

Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy.

Christian Immanuel et al. · European journal of nuclear medicine and molecular imaging · 2026
Background

Skeletal muscle radiodensity (SMD) is an emerging imaging-derived marker of muscle quality.

Purpose

This study aims to investigate the prognostic value of SMD derived from routine pretherapeutic PET/CT imaging in a large real-world mCRPC cohort treated with [¹⁷⁷Lu]Lu-PSMA-617.

Methods

In this single-center study, the largest to date cohort comprising 410 mCRPC patients was analyzed.

n = 410 mCRPC patients
Results
lower muscle quality means nearly twice the risk of dying from advanced prostate cancer
n = 410 mCRPC patients
More results

This prognostic stratification was seen in both, patients with or without PSA50 or PSA90 response, respectively.

SMD correlated with age, albumin, and PSA, but not with BMI.

“
Conclusion · 1 of 2

SMD assessed from routine pretherapeutic PET/CT is a non-invasive prognostic biomarker in patients undergoing PSMA-targeted radioligand therapy.

Conclusion · 2 of 2

Integration of host-derived imaging biomarkers such as SMD with tumor-specific parameters may improve risk stratification, prehabilitation and support future individualized treatment strategies in advanced prostate cancer.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
71.8%
most urologists never used a standard survey to assess stent symptoms
Cohort Study
SIR 1.67
young bladder cancer survivors have a higher risk of developing second cancers compared to the general population
Cohort Study
98%
98% of patients had no significant rectocele after laparoscopic double sacrocolpopexy.
Cohort Study
OR 0.10
Beyond 4000 J/ml, the odds of reintervention are 90% lower.
Randomized Trial
hazard ratio 0·67
pirarubicin instillation led to a lower risk of recurrence compared to observation
Study
3,216
This many specific enhancers were found in prostate cancer cells, not normal cells.
Study
75%
experts agreed on the recommendations for managing prostate cancer recurrence
Case-control
OR = 4.23
Higher triglycerides linked to higher odds of prostate cancer (odds, not risk)